Three months treatment with chemotherapy and radiotherapy for small cell lung cancer.
AffiliationCancer Research Campaign Department of Medical Oncology; Department of Radiotherapy, Christie.
MetadataShow full item record
AbstractFifty-five patients with inoperable but limited stage small cell carcinoma of the bronchus and a further 15 patients with contra lateral neck nodes, pleural effusions and marrow involvement were entered into the study and treated. The 3 month treatment regimen comprised 3 courses of etoposide with cyclophosphamide at 2.5 gm-2 followed by methotrexate and radiotherapy, no maintenance treatment was given. The complete response rate in the total patient group was 54% and the partial response rate 21%. The median survival was 11 months for the 70 patients, 15 months for the complete responders, and those patients with a bronchoscopically confirmed complete response survived significantly longer. There was no significant difference between the patients with strictly limited stage disease and those in the broader category. Eight patients are tumour free and alive one year or more after the end of treatment. The median followup is 17 months. Twenty-four patients were delayed 1-2 weeks during treatment because of chemotherapy induced toxicity. Six patients died probably of infection associated with leucopaenia. The majority of the patients' Karnofsky performance improved with the treatment as did their breathlessness assessed on a respiratory score. The short intensive chemotherapy regimen of 3 months produced similar results to those following more prolonged treatment regimens.
CitationThree months treatment with chemotherapy and radiotherapy for small cell lung cancer. 1985, 52 (3):327-32 Br. J. Cancer
JournalBritish Journal of Cancer
- Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer.
- Authors: Thatcher N, James RD, Steward WP, Barber PV, Feinmann D, Lawson BA, Carroll KB
- Issue date: 1985 Sep 15
- Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
- Authors: Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC
- Issue date: 1996 Mar
- A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
- Authors: Bleehen NM, Girling DJ, Machin D, Stephens RJ
- Issue date: 1993 Dec
- Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
- Authors: Murray N, Shah A, Brown E, Kostashuk E, Laukkanen E, Goldie J, Band P, Van den Hoek J, Murphy K, Sparling T
- Issue date: 1986 Sep
- Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
- Authors: Thatcher N, Lind M, Stout R, Payne C, Carroll KB, Campbell C, Moussalli H
- Issue date: 1989 Jul